November 28, 2016 - By Clifton Ray
Leerink Swann have a $34.00 price target on the stock. The price target means a potential upside of 53.85% from Juno Therapeutics (NASDAQ:JUNO)‘s last stock price. This rating was shown in a research note on Monday, 28 November.
Out of 10 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 5 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 50% are positive. $73 is the highest target while $25 is the lowest. The $42.82 average target is 93.76% above today’s ($22.1) stock price. Juno Therapeutics Inc has been the topic of 22 analyst reports since July 22, 2015 according to StockzIntelligence Inc. As per Wednesday, July 6, the company rating was initiated by Barclays Capital. As per Wednesday, November 23, the company rating was downgraded by FBR Capital. Suntrust Robinson initiated the shares of JUNO in a report on Friday, January 29 with “Buy” rating. On Friday, August 5 the stock rating was maintained by Maxim Group with “Buy”. FBR Capital initiated Juno Therapeutics Inc (NASDAQ:JUNO) rating on Tuesday, August 18. FBR Capital has “Outperform” rating and $73 price target. The company was initiated on Wednesday, November 18 by Goldman Sachs. Suntrust Robinson downgraded it to “Hold” rating and $25 target price in Friday, November 25 report. The firm has “Buy” rating given on Thursday, February 25 by Citigroup. The rating was initiated by Standpoint Research on Monday, August 24 with “Buy”. Raymond James initiated Juno Therapeutics Inc (NASDAQ:JUNO) on Thursday, June 2 with “Outperform” rating.
About 1.67 million shares traded hands. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 47.67% since April 25, 2016 and is downtrending. It has underperformed by 53.68% the S&P500.
Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 6. They expect $-0.66 earnings per share, down 22.22% or $0.12 from last year’s $-0.54 per share. After $-0.58 actual earnings per share reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.
Insitutional Activity: The institutional sentiment increased to 1.4 in Q2 2016. Its up 0.06, from 1.34 in 2016Q1. The ratio improved, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Point72 Asia (Hong Kong) Limited has invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Tocqueville Asset Management Ltd Partnership, a New York-based fund reported 34,200 shares. The Illinois-based Northern Corp has invested 0% in Juno Therapeutics Inc (NASDAQ:JUNO). Mycio Wealth Prtnrs Limited Liability Corp, a Pennsylvania-based fund reported 500 shares. Vident Investment Advisory Ltd Liability Corp owns 15,776 shares or 0.09% of their US portfolio. Hsbc Public Ltd Company holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 6,068 shares. California Employees Retirement Systems reported 79,500 shares or 0% of all its holdings. Creative Planning has 29,740 shares for 0.01% of their US portfolio. The New York-based Teachers Advisors Inc has invested 0% in Juno Therapeutics Inc (NASDAQ:JUNO). Royal State Bank Of Canada accumulated 0% or 5,942 shares. Baker Bros Advsr L P reported 80,000 shares or 0.03% of all its holdings. Barclays Public Limited Co holds 0% or 25,347 shares in its portfolio. Public Employees Retirement Association Of Colorado owns 10,824 shares or 0% of their US portfolio. Moreover, Bb Biotech Ag has 1.98% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 1.31M shares. Thompson Davis & Com last reported 0.11% of its portfolio in the stock.
Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $2.39 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
More recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Why Juno Therapeutics Inc Plummeted Today” on November 23, 2016. Also Fool.com published the news titled: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” on November 03, 2016. Marketwatch.com‘s news article titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …” with publication date: November 23, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray